331765-62-9Relevant academic research and scientific papers
MUSCARINIC M2 RECEPTOR BLOCKADE TO DELAY OR PREVENT ONSET OF PROGRESSIVE MEMORY DECLINE
-
, (2018/10/04)
Provided are methods for delaying or preventing onset of progressive memory decline by administering a muscarinic M2 receptor blocking compound to patients identified as at risk of developing a condition characterized by progressive memory decline, prior
Muscarinic M2 antagonists: Anthranilamide derivatives with exceptional selectivity and in vivo activity
Clader, John W.,Billard, William,Binch III, Herbert,Chen, Lian-Yong,Crosby Jr., Gordon,Duffy, Ruth A.,Ford, Jennifer,Kozlowski, Joseph A.,Lachowicz, Jean E.,Li, Shengjian,Liu, Charles,McCombie, Stuart W.,Vice, Susan,Zhou, Gowei,Greenlee, William J.
, p. 319 - 326 (2007/10/03)
Anthranilamide analogues such as 23 are potent and highly selective muscarinic M2 antagonists that also show good oral bioavailability and in vivo activity.
MUSCARINIC ANTAGONISTS
-
Page 10, (2010/02/06)
Amide derivatives of 1,4 di-substituted piperidine compounds of formula (I) or a pharmaceutically acceptable salt, ester or solvate thereof, wherein Q and Q are each -CH=, or one of Q and Q is -CH= and the other is -N=; X is -CH2- or (a); Y and Z are -C(R)=, or one of Y and Z is -C(R)= and the other is -N=; R is 1 to 3 substituents selected from H, halogen and alkoxy; R and R are 1 to 3 substituents selected from H, halogen, alkyl and alkoxy; and R and R are H or (C1-C6) alkyl are muscarinic antagonists usuful for treating cognitive disorders such as Alzheimer's disease. Pharmaceutical compositions and methods of preparation are also disclosed.
